• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014

tetano

Editor, Senior Moderator
Vaccine. 2016 Jun 2. pii: S0264-410X(16)30324-3. doi: 10.1016/j.vaccine.2016.05.034. [Epub ahead of print]
[h=1]Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014.[/h] Radin JM[SUP]1[/SUP], Hawksworth AW[SUP]2[/SUP], Myers CA[SUP]2[/SUP], Ricketts MN[SUP]2[/SUP], Hansen EA[SUP]2[/SUP], Brice GT[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Factors, such as age, comorbidities, vaccine type, herd immunity, previous influenza exposure, and antigenic shift, may impact the immune response to the influenza vaccine, protection against circulating strains, and antibody waning. Evaluating vaccine effectiveness (VE) is important for informing timing of vaccine administration and evaluating overall vaccine benefit.
[h=4]METHODS:[/h] VE was assessed using febrile respiratory illness surveillance among Department of Defense non-active duty beneficiaries from influenza seasons 2010-2011 through 2013-2014. Respiratory specimens were taken from participants meeting the case definition and tested by polymerase chain reaction for influenza. VE was calculated using logistic regression and by taking 1 minus the odds ratio of being vaccinated in the laboratory confirmed positive influenza cases versus laboratory confirmed negative controls.
[h=4]RESULTS:[/h] This study included 1486 participants. We found an overall adjusted VE that provided significant and fairly consistent protection ranging from 54% to 67% during 0-180days postvaccination. This VE dropped to -11% (95% confidence interval: -102% to 39%) during 181-365days.
[h=4]CONCLUSIONS:[/h] Our study found moderate VE up to 6months postvaccination. Since the influenza season starts at different times each year, optimal timing is difficult to predict. Consequently, early influenza vaccination may still offer the best overall protection.
Copyright ? 2016. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Age groups; Influenza; Postvaccination; Vaccine effectiveness

PMID: 27265447 [PubMed - as supplied by publisher]
 
Back
Top Bottom